Avid Bioservices Inc (CDMO)

[rhyino]

Cp

One thing that I found interesting from when king was wrapping up. He stated that bms had a immunoncology drug that had two similar look ins. The trial was stopped at the second loook in. Then the drug was approved 3 months later.

Another point that was addressed was the phase 3 trial design and why it is setup how it is. At 23:40 " another good point is we do have this second interm data look which could be very important because if we did see these same results as we saw from the phase 2 study at that point therw really could be a positive end point in this clinical trial".

Rhyino